NCT00119392 · OUTCOME

Engraftment and Hematopoietic Toxicity

Yttrium Y 90 Ibritumomab Tiuxetan, Fludarabine, Radiation Therapy, and Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma · Source last updated 2018-06-29

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: MEDIAN
Unit: days
Interval / dispersion: Full Range
Time frame: At day +100

What was measured

Median number of days after transplantation to a neutrophil count less than 500 neutrophils per microliter and a platelet count less than 50,000 platelets per microliter.

Groups in this outcome

Treatment (90Y Ibritumomab Tiuxetan, Hematopoietic Transplant)

See Detailed Description rituximab: Given IV cyclosporine: Given orally fludarabine phosphate: Given IV mycophenolate mofetil: Given orally yttrium Y 90 ibritumomab tiuxetan: Given IV peripheral blood stem cell transplantation: Undergo transplantation allogeneic hematopoietic stem cell transplantation: Undergo transplantation total-body irradiation: Undergo TBI

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
Treatment (90Y Ibritumomab Tiuxetan, Hematopoietic Transplant)	40

Reported measurements

Neutrophils

Values in days · Interval/dispersion: Full Range
Group	Value	Spread	Lower	Upper	Comment
Treatment (90Y Ibritumomab Tiuxetan, Hematopoietic Transplant)	17	Not reported	0	34	Not reported

Platelets

Values in days · Interval/dispersion: Full Range
Group	Value	Spread	Lower	Upper	Comment
Treatment (90Y Ibritumomab Tiuxetan, Hematopoietic Transplant)	11	Not reported	0	147	Not reported

Complete source fields

classes

categories
measurements
group Id
OG000
lower Limit
0
upper Limit
34
value
17
title
Neutrophils
categories
measurements
group Id
OG000
lower Limit
0
upper Limit
147
value
11
title
Platelets

denoms

counts
group Id
OG000
value
40
units
Participants

description

Median number of days after transplantation to a neutrophil count less than 500 neutrophils per microliter and a platelet count less than 50,000 platelets per microliter.

dispersion Type

Full Range

groups

description
See Detailed Description rituximab: Given IV cyclosporine: Given orally fludarabine phosphate: Given IV mycophenolate mofetil: Given orally yttrium Y 90 ibritumomab tiuxetan: Given IV peripheral blood stem cell transplantation: Undergo transplantation allogeneic hematopoietic stem cell transplantation: Undergo transplantation total-body irradiation: Undergo TBI
id
OG000
title
Treatment (90Y Ibritumomab Tiuxetan, Hematopoietic Transplant)

param Type

MEDIAN

reporting Status

POSTED

time Frame

At day +100

title

Engraftment and Hematopoietic Toxicity

type

SECONDARY

unit Of Measure

days

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice